Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770753 | 0.89 | GRIN2B (0.36) | MPLSOS1PRKCAPRKCQLRRK2 | |
| SCHEMBL23770694 | 0.87 | GALR2 (0.40) | SOS1 | |
| SCHEMBL23770850 | 0.87 | LRRK2 (0.33) | LRRK2 | |
| SCHEMBL23770471 | 0.87 | SOS1 (0.34) | SOS1 | |
| SCHEMBL23770453 | 0.86 | CYP1A2 (0.40) | SOS1 | |
| SCHEMBL23770822 | 0.85 | MPL (0.33) | MPLPRKCAPRKCQLRRK2CLK2 | |
| SCHEMBL23770593 | 0.85 | GALR2 (0.33) | — | |
| SCHEMBL23770810 | 0.85 | MPL (0.32) | MPLPRKCAPRKCQ | |
| SCHEMBL23770793 | 0.84 | MPL (0.38) | MPLLRRK2 | |
| SCHEMBL23770489 | 0.82 | HSD11B1 (0.33) | MPLLRRK2CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |